Evaluation of the effectiveness of Different Medications in the Resolution of channel inflammations

Clinical Evaluation of Different Intracanal Medications on the Periapical Levels of Resolvins and Lipoxin - New Endodontic Perspectives

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

REBEC

Registry ID

RBR-4mrrhh

Enrollment

Unknown

Registered

2018-04-30

Start date

2017-07-12

Completion date

Unknown

Last updated

2025-10-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Dental Pulp Necrosis

Interventions

Group 1 Number of participants: 15 Procedures performed: Endodontic treatment Medication: Calcium hydroxide with serum Availability: 1:1 Medication time: 14 days Method of administration: intracanal p

Drug

E06.397.778

E06.397.778.889

E06.397.778.778

Eligibility

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Patients in adulthood; Need for endodontic treatment; Permanent teeth with primary endodontic infection; Unirradicular; Presence of a single canal and periapical lesion; Absence of periodontal pockets greater than 4 mm; No mobility.

Exclusion criteria

Exclusion criteria: Teeth that can not be insulated with the rubber dam; With root fracture; Exposure of the pulp chamber; Patients who have used antibiotics or antifungals in the last 3 months; Patients with systemic disease.

Design outcomes

Primary

Measure	Time frame
Expected outcome 1-Increased release of local lipid mediators (RvE1, RvD2 and LxA4) with resolution or significant reduction of the periapical inflammatory process, verified by the enzyme-linked immunosorbent assay (ELISA) method, which allows detecting amounts of protein of the order of nanograms (10-9 g) from the observation of a variation of at least 5% in the pre- and post-intervention measurements.	—

Measure

Time frame

Expected outcome 1-Increased release of local lipid mediators (RvE1, RvD2 and LxA4) with resolution or significant reduction of the periapical inflammatory process, verified by the enzyme-linked immunosorbent assay (ELISA) method, which allows detecting amounts of protein of the order of nanograms (10-9 g) from the observation of a variation of at least 5% in the pre- and post-intervention measurements.

—

Secondary

Measure	Time frame
Expected outcome 2- Reduction of bacterial count by colony-forming unit counts (CFU / ml), compared to values at the beginning of treatment, based on a variation of at least 5% in pre and post-intervention measurements .;Expected outcome 3 - Reduction in endotoxin levels by means of the Chromokinetic Test of Limulus Amebocyte Lysates (KQCL) compared to the initial values from the observation of a variation of at least 5% in the pre and post intervention measurements.	—

Measure

Time frame

Expected outcome 2- Reduction of bacterial count by colony-forming unit counts (CFU / ml), compared to values at the beginning of treatment, based on a variation of at least 5% in pre and post-intervention measurements .;Expected outcome 3 - Reduction in endotoxin levels by means of the Chromokinetic Test of Limulus Amebocyte Lysates (KQCL) compared to the initial values from the observation of a variation of at least 5% in the pre and post intervention measurements.

—

Countries

Brazil

Contacts

Public ContactBruna Jordão Motta Corazza

Universidade Estadual Paulista Júlio de Mesquita Filho - Campus São José dos Campos

brunajordao1991@gmail.com+55-012-991512822

Outcome results

None listed

Source: REBEC (via WHO ICTRP)